• Adefovir (GS-0393): From Mechanism to Translation

  2026-08-25

  A mechanism-first perspective on Adefovir and GS-0393 for HBV antiviral research, assay design, renal transporter studies, and translational risk assessment.

• Adefovir Workflows for HBV and OAT1 Studies

  2026-08-25

  Adefovir, also known as GS-0393, supports two distinct research workflows: mechanistic hepatitis B virus replication studies and quantitative OAT1 transporter assays. This guide connects dose selection, aqueous handling, assay controls, and troubleshooting so investigators can distinguish true antiviral activity from exposure, solubility, or transporter artifacts.

• CA-074 Me: Cathepsin B Inhibitor Guide

  2026-08-24

  A scenario-based guide to using CA-074 Me (Cathepsin B inhibitor), SKU A8239, in viability, apoptosis, lysosomal, and necroptosis workflows. It connects biochemical potency, solvent handling, controls, and vendor-selection criteria with current evidence on lysosomal membrane permeabilization.

• Trypsin as a Translational Protease Strategy

  2026-08-24

  A thought-leadership guide to using Trypsin as both a mechanistic perturbation and a controlled research reagent, linking proteolytic design to osteoarthritis biology, cell-state studies, viral membrane fusion, wound healing research, and translational assay strategy.

• Adefovir (GS-0393): From Mechanism to Translation

  2026-08-23

  A translational perspective on Adefovir as a selective HBV DNA polymerase inhibitor and OAT1 probe, connecting molecular mechanism, assay design, exposure alignment, resistance biology, and renal safety strategy for hepatitis B virus research.

• S-Adenosylmethionine: From Methyl Donor to CNS Strategy

  2026-08-22

  S-Adenosylmethionine, also called Ademetionine or SAMe, is more than a generic methyl donor. Its position at the intersection of epigenetic regulation, neurotransmitter metabolism, transsulfuration, and cellular growth signaling makes it a strategic variable in translational research. This article connects mechanism, assay design, product selection, and neurological relevance to help researchers use SAM with greater experimental precision.

• nor-Binaltorphimine dihydrochloride: KOR Assays

  2026-08-22

  Build more discriminating opioid receptor signaling research workflows with nor-Binaltorphimine dihydrochloride, a selective κ-opioid receptor antagonist for separating KOR-dependent effects from MOR-driven responses. This guide translates a brain-to-spinal pain circuit study into practical assay design, stock-preparation choices, controls, and troubleshooting steps.

• LPS Protection of Macrophages Against Antitumor Drugs

  2026-08-21

  Qiao and colleagues show that lipopolysaccharide protects RAW264.7 macrophages from antitumor drug injury through a redox- and transport-associated mechanism involving system Xc−, glutathione, and ABCC1. The findings separate this protective response from canonical TLR4 and caspase-11 signaling and provide a useful framework for studying immune-cell preservation during chemotherapy.

• GSK343: EZH2 Inhibitor Workflow

  2026-08-20

  GSK343 is a cell-permeable, SAM-competitive EZH2 inhibitor for testing how PRC2-driven H3K27me3 shapes gene expression and cancer phenotypes. This workflow connects quantitative chromatin assays with breast, prostate, and TERT-focused models while emphasizing controls, solubility, and interpretation limits.

• Novobiocin: Assay Design Beyond MIC Testing

  2026-08-20

  Novobiocin is an aminocoumarin antibiotic whose value extends beyond a single MIC measurement. This guide shows how to connect growth, mechanistic, synergy, host-cell, and translational readouts into a more defensible antimicrobial assay strategy.

• BRD4–RAC1 Co-targeting in Breast Cancer

  2026-08-19

  A 2021 study showed that simultaneous inhibition of BRD4 and RAC1 suppresses breast cancer growth, migration, stem-like behavior, and xenograft tumorigenesis across molecular subtypes. Its key mechanistic contribution was to connect dual pathway inhibition with disruption of the c-MYC–G9a–FTH1 axis and downregulation of HDAC1-associated chromatin regulation.

• Firefly Luciferase mRNA: Assay Workflows

  2026-08-19

  Build sensitive reporter assays, delivery screens, and in vivo imaging workflows with a capped, modified Firefly Luciferase mRNA. Its Cap1 structure, 5-moUTP chemistry, and optimized poly(A) tail support sustained expression while the reference study shows why expression and immune readouts should be analyzed separately by biological sex.

• BRD4770: G9a Inhibition Workflow for Cancer Models

  2026-08-18

  BRD4770 provides a practical route to connect G9a enzymatic inhibition with H3K9 methylation loss, senescence, and cancer-cell growth phenotypes. This workflow emphasizes formulation control, time-resolved epigenetic readouts, and assay choices informed by breast and pancreatic cancer models.

• DHODH Inhibition and TP53 in Nasopharyngeal Cancer

  2026-08-18

  Dong et al. identify pyrimidine biosynthesis and DHODH as metabolically relevant vulnerabilities in nasopharyngeal carcinoma, showing that BAY2402234 suppresses tumor-associated phenotypes through a TP53-dependent mechanism. The study combines multi-dataset bioinformatics with cellular pharmacology, transcriptomics, and TP53 knockdown, providing a framework for evaluating metabolic interventions in tumors with relatively preserved TP53 signaling.

• AL-8810: Prostaglandin F2α Antagonist Workflows

  2026-08-17

  Learn how AL-8810 enables controlled dissection of FP receptor signaling in endometrial, vascular, and smooth muscle models. This practical guide combines assay design, concentration selection, pathway validation, and troubleshooting around PGF2α-driven ERK1/2, MMP-2, and vascular responses.

8467 records 1/565 page Next 12345 下5页 Last page